BioStock Investor Pitch: Alligator Bioscience
Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for the treatment of solid tumours in a collaboration with Aptevo Therapeutics. Now the company is carrying out a rights issue of approximately 199 million SEK. Alligator’s CEO Søren Bregenholt tells us more about ongoing activities in a BioStock Investor Pitch today at 09.15 am.Watch the presentation by Søren Bregenholt at biostock.se: https://www.biostock.se/en/2023/05/biostock-investor-pitch-